Last 22 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.34 | — | — | — | — | — | — | 5.17 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.80 | 5.91 | 8.79 | 10.22 | 7.64 | 27.30 | 38.68 | 2.98 | 170.09 | 412.00 | — | — | — | 15897.64 | 7667.75 | — | 654.90 | 214.22 | 124.11 | 77.39 | 165.40 |
| — | -78.4% | -77.3% | +242.5% | -95.5% | -93.4% | — | — | — | -97.4% | — | — | — | +7321.3% | +6078.3% | — | +296.0% | +68.0% | -30.9% | — | — | |
| P/B Ratio | 3.51 | 63.58 | 13.01 | 10.05 | 6.73 | 8.92 | 5.39 | 4.02 | 7.00 | 3.83 | 4.40 | 2.28 | 1.52 | 2.56 | 2.35 | 2.94 | 19.13 | — | 1.12 | — | 1.05 |
| — | +612.4% | +141.4% | +149.7% | -3.9% | +133.1% | +22.3% | +76.3% | +359.8% | +49.6% | +87.5% | -22.3% | -92.0% | — | +109.3% | — | +1718.7% | — | -72.7% | — | — | |
| P/FCF | — | — | — | — | — | — | — | 6.20 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | 5.20 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | 4.89 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.8% | 61.8% | 72.3% | 88.6% | 74.8% | 68.3% | 49.3% | 95.5% | 94.6% | -1279.2% | — | — | — | -71980.0% | -32160.0% | — | -1906.9% | -837.5% | -717.9% | -419.1% | -870.1% |
| — | -9.5% | +46.8% | -7.2% | -20.9% | +105.3% | — | — | — | +98.2% | — | — | — | -8494.6% | -4379.4% | — | -119.2% | -404.4% | -332.4% | — | — | |
| Operating Margin | -212.9% | -182.6% | -265.2% | -147.6% | -163.7% | -302.9% | -466.3% | 54.5% | -1051.6% | -3068.0% | — | — | — | -206030.0% | -93565.0% | — | -3507.9% | -1367.2% | -1070.7% | -658.0% | -1063.6% |
| — | +39.7% | +43.1% | -370.8% | +84.4% | +90.1% | — | — | — | +98.5% | — | — | — | -14969.0% | -8638.4% | — | -229.8% | -550.6% | -409.5% | — | — | |
| Net Margin | -203.3% | -185.2% | -267.3% | -147.1% | -157.4% | -285.6% | -425.7% | 57.7% | -925.0% | -2503.2% | — | — | — | -173700.0% | -74805.0% | — | -3483.1% | -1383.6% | -1093.5% | -681.7% | -1100.4% |
| — | +35.1% | +37.2% | -355.1% | +83.0% | +88.6% | — | — | — | +98.6% | — | — | — | -12454.0% | -6740.8% | — | -216.5% | -528.9% | -397.0% | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -92.3% | -168.9% | -69.1% | -31.6% | -30.1% | -21.3% | -14.0% | 21.8% | -9.2% | -5.7% | -4.5% | -3.1% | -6.1% | -6.8% | -5.6% | -9.7% | -25.4% | -5.2% | -5.5% | -3.4% | -1.7% |
| — | -692.7% | -394.2% | -244.6% | -227.4% | -273.8% | -208.6% | +812.2% | -50.2% | +16.4% | +19.2% | +68.3% | +75.9% | -32.3% | -1.2% | -182.7% | -1392.2% | -298.2% | -339.0% | — | — | |
| ROA | -50.5% | -23.2% | -19.7% | -11.8% | -14.9% | -14.0% | -10.0% | 17.6% | -8.7% | -5.6% | -4.5% | -3.0% | -5.9% | -6.6% | -5.4% | -9.0% | -15.3% | -3.6% | -3.9% | -2.5% | -1.6% |
| — | -65.7% | -97.0% | -167.2% | -71.3% | -151.6% | -124.0% | +690.0% | -48.5% | +15.1% | +17.5% | +66.9% | +61.8% | -83.0% | -39.6% | -261.9% | -850.4% | -188.7% | -219.0% | — | — | |
| ROIC | -71.7% | -29.8% | -29.8% | -24.0% | -34.4% | -21.5% | -14.1% | 19.3% | -9.6% | -6.6% | -6.0% | -4.5% | -8.8% | -10.2% | -11.9% | -40.1% | — | — | — | — | -27.8% |
| — | -38.3% | -111.1% | -224.7% | -258.5% | -224.6% | -134.0% | +523.5% | -9.2% | +34.8% | +49.2% | +88.7% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.84 | 13.72 | 1.57 | 0.84 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | — | 0.02 | — | 0.02 |
| — | +158694.4% | +493435.7% | +514215.2% | +1942.5% | +1062.4% | -67.1% | -86.2% | -63.1% | -51.3% | -41.3% | -32.7% | -99.4% | — | -91.3% | — | +1217.3% | — | +100.8% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.28 | 3.48 | 4.94 | 7.28 | 6.66 | 6.17 | 11.00 | 14.26 | 12.56 | 32.82 | 60.90 | 96.85 | 21.87 | 25.37 | 27.18 | 51.01 | 4.69 | 6.08 | 17.65 | 7.42 | 19.90 |
| — | -43.7% | -55.1% | -49.0% | -47.0% | -81.2% | -81.9% | -85.3% | -42.6% | +29.4% | +124.1% | +89.9% | +365.9% | +317.0% | +54.0% | +587.7% | -76.4% | -73.9% | -45.9% | — | — | |
| Quick Ratio | 7.06 | 3.28 | 4.77 | 7.06 | 6.51 | 5.98 | 10.74 | 14.04 | 12.52 | 32.82 | 60.90 | 96.85 | 21.87 | 25.37 | 27.18 | 51.01 | 4.69 | 6.08 | 17.65 | 7.42 | 19.90 |
| — | -45.1% | -55.6% | -49.7% | -48.0% | -81.8% | -82.4% | -85.5% | -42.8% | +29.4% | +124.1% | +89.9% | +365.9% | +317.0% | +54.0% | +587.7% | -76.4% | -73.9% | -45.9% | — | — | |
| Interest Coverage | -64.94 | -24.15 | -23.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SPRY stock.
ARS Pharmaceuticals, Inc.'s current P/E is -2.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ARS Pharmaceuticals, Inc.'s current operating margin is -212.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ARS Pharmaceuticals, Inc.'s business trajectory between earnings reports.